The Role of Oxytocin and Interoception in Functional Neurological Disorder

March 24, 2025 updated by: University of Fribourg
The main goal of this project is to better understand the role of oxytocin and Interoception in FND. More specifically oxytocin's association with precision weighing, prediction errors and priors in the interoceptive domains will be investigated. To this end, several methods will be employed: analysis of interoceptive accuracy and sensibility (interoceptive tasks and questionnaires), biomarkers of oxytocin (peripheral, endogenous oxytocin), genetic oxytocin markers (such as allele-frequency in the oxytonergic receptor gene), epigenetics (methylation rates of genes related to oxytocin), neuroactivity (EEG).

Study Overview

Detailed Description

The primary objective is to explore interoceptive processing during a behavioural (interoceptive) tasks and its association to the oxytocin (OT) system in patients affected by a functional neurological disorder (FND), in comparison to healthy controls (HC).

Concerning interoception, as primary outcome, it is hypothesized that:

A) FND patients are less interoceptive (judged by objectively measured accuracy) compared to HC in the interoceptive tasks.

Concerning OT, as primary outcome, it is hypothesized that:

B) The OT level is correlated with interoception tasks; specifically the adaption of precision weighting

The secondary objectives are to:

  • Explore the validity and reliability of different interoceptive tasks (e.g. respiratory, cardiovascular, emotional tasks)
  • Explore neuronal regions associated with interoceptive processing and interoceptive accuracy in FND compared to HC
  • Investigate whether FND patients have a higher interoception trait-prediction error (discrepancy between subjective and objective interoception scores) and whether this correlates with their symptom severity
  • Explore the association of the breathing cycle and the voluntary initiation of mental or motor actions, and its readiness potential
  • Explore peripheral biomarkers (e.g. salivary OT) in FND patients, compared to HC
  • Explore the differences in (epi)genetic profile associated with the OT-system in FND compared to HC
  • Investigate the association of the OT-system and traumatic childhood experience, attachment styles and sexual functioning in patients of FND compared to HC

Study Type

Observational

Enrollment (Actual)

110

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bern, Switzerland, 3010
        • Inselspital
      • Fribourg, Switzerland, 1700
        • University of Fribourg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

FND patients Participants who are patients will be recruited from the in- and out-patients pool of the Clinic for Neurology of the Hospital of Fribourg and the Inselspital. At both, the treating physician will identify suitable patients (i.e. patients who fulfil the clinical requirement for FND as described in the DSM-5). The treating physician will ask these patients whether they would like to be approached by the Investigator (or his/her designee) concerning a scientific study. In case of affirmative response, the Investigator will approach the patients, inform them about the study.

Healthy control Healthy controls will be recruited among students, collaborators, and visitors of the University of Fribourg and Bern, the Hospital of Fribourg and the Inselspital. They will be recruited by flyer, by word-of-mouth and through advertisements in public media.

Description

Inclusion Criteria for Patients:

  • A diagnosis of FND according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) diagnostic criteria
  • Capable of judgement
  • Willing to participate in the study (by signing the informed consent form)

Inclusion Criteria for Healthy controls:

  • Capable of judgement
  • Willing to participate in the study (by signing the informed consent form)

Exclusion Criteria for Patients:

  • Presence of comorbid disorders such as psychosis or major depression with suicidal risk
  • History of actual or suspected epilepsy
  • Past surgery in the brain
  • Cardio-vascular disease
  • Implanted Investigational Medicinal Products (e.g. cochlear implants, neurostimulators, cardiac pacemakers)
  • History of alcohol or drug abuse
  • For female participants: breastfeeding, pregnancy (a standard urine pregnancy test will be provided)
  • <6h prior application prostaglandin
  • Long QT-syndrome
  • Inability to follow the procedures of the study, e.g. due to language problems

Exclusion Criteria for Healthy controls:

  • History of actual or suspected epilepsy
  • Past surgery in the brain
  • Cardio-vascular disease
  • Implanted Investigational Medicinal Products (e.g. cochlear implants, neurostimulators, cardiac pacemakers)
  • History of alcohol or drug abuse
  • For female participants: breastfeeding, pregnancy (a standard urine pregnancy test will be provided)
  • <6h prior application prostaglandin
  • Long QT-syndrome
  • Inability to follow the procedures of the study, e.g. due to language problems

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
FND Patients
Group of patients with functional neurological disorders
The RRST measures interoception on the domain of the breath and thus allows its (non-invasive) manipulation. The RRST apparatus includes a step motor that moves a wedge piece back and forth to change the obstruction level in the breathing circuit. This fully automated apparatus will change the breathing obstruction level via a computer-controlled algorithm. The patient breath by the month though this device.
Other Names:
  • Respiration resistance device
The HBT measures interoception on the domain of the cardiovascular system, by assessing how accurate participants perceive their own heartbeat. After each time window participants will be asked how many heartbeats they counted, which will be compared to the actual heartbeat measured via electrocardiography (ECG).
Other Names:
  • ECG
The HEP is computed by averaging EEG signals time-locked to specific peaks of simultaneously measured ECG signals. Therefore both an ECG and an EEG will be set up for the participants. The task during the HEP is to simply focus on interoceptive tones (the own heartbeat) with a control condition of focusing on exteroceptive tones (sounds played). A further condition of HEP measurement is the cardio-audio synchronization. Hereby, participants will be instructed to passively listen to sounds presented to them via in-ear phones while further fixating the cross.
Other Names:
  • ECG + EEG
Additionally we also link the interoceptive domain of the breath to a well-known and established agency task measuring conscious intention. Participants will do two versions of the Libet taks while simultaneously recording their EEG and breathing signals with a respiratory belt.
Other Names:
  • Respiration belt + EEG
Healthy control
Age matched group control of healthy participant
The RRST measures interoception on the domain of the breath and thus allows its (non-invasive) manipulation. The RRST apparatus includes a step motor that moves a wedge piece back and forth to change the obstruction level in the breathing circuit. This fully automated apparatus will change the breathing obstruction level via a computer-controlled algorithm. The patient breath by the month though this device.
Other Names:
  • Respiration resistance device
The HBT measures interoception on the domain of the cardiovascular system, by assessing how accurate participants perceive their own heartbeat. After each time window participants will be asked how many heartbeats they counted, which will be compared to the actual heartbeat measured via electrocardiography (ECG).
Other Names:
  • ECG
The HEP is computed by averaging EEG signals time-locked to specific peaks of simultaneously measured ECG signals. Therefore both an ECG and an EEG will be set up for the participants. The task during the HEP is to simply focus on interoceptive tones (the own heartbeat) with a control condition of focusing on exteroceptive tones (sounds played). A further condition of HEP measurement is the cardio-audio synchronization. Hereby, participants will be instructed to passively listen to sounds presented to them via in-ear phones while further fixating the cross.
Other Names:
  • ECG + EEG
Additionally we also link the interoceptive domain of the breath to a well-known and established agency task measuring conscious intention. Participants will do two versions of the Libet taks while simultaneously recording their EEG and breathing signals with a respiratory belt.
Other Names:
  • Respiration belt + EEG

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference of interoception behavioural scores between FND patients and Healthy controls
Time Frame: 1 day
Assessment of the difference between interoception tasks scores between these groups. These scores evaluated the interoception processing abilities of patient/control.
1 day
Difference in brain electrophysiology during interoception processing between FND patients and Healthy controls
Time Frame: 1 day
Assessment of the difference Evoked Related potential (ERPs) during interoception taks between these groups.
1 day
Association between oxytocin system and interoception and its difference between FND patients and Healthy controls
Time Frame: 1 day
Study of the correlation between oxytocin system and interoception indices. Oxytocin system was studied with oxytocin concentration (saliva) and genetic markers (blood analysis).
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Oxytocin concentration (Saliva sampling)
Time Frame: 1 day
During the day of the experimental session, 4 samples of saliva at different time are collected. These sample will be used to determine the concentration of oxytocin during the day (30 min post awakening, 30min after lunch, at tasks, upon the arrival for experimental session, after the completion of all tasks).
1 day
Epigenetic profile
Time Frame: 1 day
Blood sample are used for genetic analysis on the oxytocin markers (such as allele-frequency in the oxytonergic receptor gene). Correlation of this with interoceptive scores.
1 day
Respiratory Resistance Sensitivity
Time Frame: 1 day
Difference of accuracy between FND patients and healthy control in the respiratory resistance sensitivity task.
1 day
Behavioral measure: heartbeat counting
Time Frame: 1 day
Difference of accuracy between FND patients and healthy control to count the number of their own heartbeats.
1 day
Electrophysiological measure (EEG): Heartbeat evoked potential (HEP) task1
Time Frame: 1 day
First, study the HEP difference between interoceptive tones (the own heartbeat) with a control condition of focusing on exteroceptive tones (sounds played). Then comparison between FND patients and healthy control.
1 day
Electrophysiological measure (EEG): Heartbeat evoked potential (HEP) task2
Time Frame: 1 day
First, study the difference of mismatch negativity (MMN) evoked potential either if external tone was synchronous or asynchronous with heartbeat. Then comparison between FND patients and healthy control.
1 day
Neurophysiological measures: Correlation between agency task and respiration cycle (Libet)
Time Frame: 1 day
Study of the correlation between a free will key press and the state in respiration cycle. Then comparison of the results between FND patients and healthy control.
1 day
Electrophysiological measure (EEG): the readiness potential (Libet)
Time Frame: 1 day
Analysing the readiness potential related with the motor movement in the implicit compared to the explicit trigger. Then comparison of the results between FND patients and healthy control.
1 day
The localization of neuronal activity derived from EEG during interoceptive tasks, and during resting state
Time Frame: 1 day
Use of the EEG signal during cardiac interception task (HEP),agency task (Libet) and resting to estimate the source generator of brain activities (inverse solution).
1 day
Behavioral measure: Correlation between oxytocin and clinical questionaire
Time Frame: 1 day
Correlating the scores or categories of childhood trauma, attachment style and sexual functioning to oxytocin levels.
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 5, 2023

Primary Completion (Actual)

January 24, 2025

Study Completion (Actual)

January 24, 2025

Study Registration Dates

First Submitted

September 20, 2023

First Submitted That Met QC Criteria

October 9, 2023

First Posted (Actual)

October 16, 2023

Study Record Updates

Last Update Posted (Actual)

March 27, 2025

Last Update Submitted That Met QC Criteria

March 24, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Functional Neurological Disorder

Clinical Trials on Respiration resistance sensitivity task (RRST)

Subscribe